Ex vivo treatment of myeloma cells by 4-HC, VP-16, LAK cells and antibodies. Academic Article uri icon

Overview

abstract

  • To assess the usefulness of 4-hydroperoxycyclophosphamide (4-HC) and Etoposide (VP-16) as a purging agent for myeloma cells in bone marrow ex-vivo, myeloma cell lines (SK-RCS-1, RPMI-8226), lymphoma cell line (SK-DHL-2) and normal bone marrow (BM) cells were treated at different concentrations of 4-HC, VP-16. In separate experiments, LAK cells or antibodies were also used to treat the above cell lines. Clonogenic tumor cells from all three cell lines could be reduced by more than 4 logs, when treated alone or as a mixture with irradiated normal bone marrow cells at a 4-HC concentration of 60 mumol/l. Under similar conditions, approximately 1% of normal BM myeloid progenitor granulocyte-macrophage colony forming cells (CFU-GM) survived. The results with LAK cells and antibodies were also encouraging. These observations support the use of various purging methods for myeloma cells for autologous bone marrow transplantation.

publication date

  • January 1, 1989

Research

keywords

  • Antibodies, Monoclonal
  • Cell Separation
  • Cyclophosphamide
  • Etoposide
  • Killer Cells, Natural
  • Multiple Myeloma

Identity

Scopus Document Identifier

  • 0024935106

Digital Object Identifier (DOI)

  • 10.1111/j.1600-0609.1989.tb01511.x

PubMed ID

  • 2627987

Additional Document Info

volume

  • 51